Edition:
United States

Express Scripts Holding Co (ESRX.OQ)

ESRX.OQ on NASDAQ Stock Exchange Global Select Market

75.65USD
18 May 2018
Change (% chg)

-- (--)
Prev Close
$75.65
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,603,412
52-wk High
$85.05
52-wk Low
$55.80

Select another date:

Wed, May 16 2018

BRIEF-Express Scripts On Track To Close Deal With Cigna Before End Of Year

* EXPRESS SCRIPTS HOLDING CO SAYS "WE ARE ON TRACK TO CLOSE" DEAL WITH CIGNA "BEFORE THE END OF THIS YEAR, AS PLANNED" - SEC FILING Source text: (https://bit.ly/2GpTvja) Further company coverage:

Cigna first quarter profit beats but shares drop on Express Scripts worries

Cigna Corp reported a better-than-expected quarterly profit and raised its full-year forecast on Thursday, but investors remained concerned about its planned $52 billion acquisition of Express Scripts Holding Co , sending shares 2.6 percent lower.

UPDATE 3-Cigna 1st-qtr profit beats but shares drop on Express Scripts worries

May 3 Cigna Corp reported a better-than-expected quarterly profit and raised its full-year forecast on Thursday, but investors remained concerned about its planned $52 billion acquisition of Express Scripts Holding Co , sending shares 2.6 percent lower.

BRIEF-Express Scripts Reports Q1 Adjusted Earnings Per Share $1.77

* Q1 EARNINGS PER SHARE VIEW $1.76 -- THOMSON REUTERS I/B/E/S

Regeneron/Sanofi cut heart drug price to $4,500-$6,600 for Express Scripts

Regeneron Pharmaceuticals Inc and Sanofi SA will slash the price of their expensive cholesterol drug for Express Scripts Holdings Co customers in exchange for greater patient access, with some savings to be shared with consumers, the companies said on Tuesday.

UPDATE 3-Regeneron/Sanofi cut heart drug price to $4,500-$6,600 for Express Scripts

May 1 Regeneron Pharmaceuticals Inc and Sanofi SA will slash the price of their expensive cholesterol drug for Express Scripts Holdings Co customers in exchange for greater patient access, with some savings to be shared with consumers, the companies said on Tuesday.

Amgen says Express Scripts exclusion impacts 2,000 Repatha patients

NEW YORK, May 1 Express Scripts Holding Co's decision to exclude Repatha from its national list of covered drugs, which is followed by thousands of corporations and health plans, impacts 2,000 patients now on Amgen's cholesterol drug Repatha, Amgen said in an emailed statement on Tuesday.

BRIEF-Regeneron And Sanofi To Lower Net Price Of Praluent For Express Scripts Patients

* REGENERON AND SANOFI TO LOWER NET PRICE OF PRALUENT® (ALIROCUMAB) INJECTION IN EXCHANGE FOR STRAIGHTFORWARD, MORE AFFORDABLE PATIENT ACCESS FOR EXPRESS SCRIPTS PATIENTS

Sanofi/Regeneron cut Praluent drug price in Express Scripts deal

May 1 Sanofi and Regeneron Pharmaceuticals said on Tuesday they had agreed to cut the price of their potent cholesterol drug, Praluent, under a deal with Express Scripts, the largest U.S. manager of prescription benefits.

Regeneron/Sanofi to cut price of heart drug in Express Scripts deal

May 1 Regeneron Pharmaceuticals and Sanofi will cut the net price of their expensive cholesterol drug for Express Scripts customers in exchange for greater patient access, with some savings to be shared with consumers, the companies said on Tuesday.

Select another date: